ElastiK° Skin | Skin in Evolution™
MENOPAUSE, WEIGHT LOSS AND SKIN CHANGES: WHAT'S ACTUALLY HAPPENING
By Marc McKee, Founder of ElastiK° Skin
TL;DR: THE ESSENTIAL POINTS
- A significant proportion of UK women using GLP-1 medications are also navigating perimenopause or menopause. These two transitions affect skin through overlapping but distinct mechanisms.
- Oestrogen decline can drive major collagen loss during menopause. This happens on top of the collagen disruption that rapid GLP-1 weight loss may create.
- The combined effect can be greater than either menopause or GLP-1 weight loss alone. Skin may experience dual collagen suppression, dual barrier compromise, and dual volume loss.
- The skincare response needs to address both processes simultaneously. The same ingredient categories are relevant, but the protocol needs to account for greater skin vulnerability.
- ElastiK°'s Skin in Evolution™ System was designed for transformation skincare. Its formulations are appropriate for the compounded menopause and GLP-1 skin context.
There is a conversation happening in GP surgeries, menopause clinics, and online communities across the UK that the skincare industry has almost entirely missed.
It is the conversation about what happens to your skin when you are going through menopause and losing significant weight on GLP-1 medication at the same time.
Two of the most significant hormonal and physiological transitions a woman's body can experience are happening simultaneously.
In the same skin.
With compounding effects.
And neither a menopause skincare brand nor a weight loss brand is fully equipped to address that picture on its own.
A growing number of UK women in their 40s and 50s are in exactly this position.
GLP-1 medications are widely prescribed privately, and perimenopause and menopause peak in the same decade.
The intersection is not rare.
It is the lived reality for a substantial number of people using these medications.
This article is the honest, science-grounded explanation of what is happening in that intersection, and what the Skin in Evolution™ System does about it.
01. WHAT MENOPAUSE DOES TO SKIN: THE BIOLOGY
Oestrogen has a direct and profound effect on skin quality.
It stimulates fibroblast collagen production, maintains skin thickness, supports hydration of the extracellular matrix, and helps regulate sebum production.
When oestrogen levels decline during perimenopause and menopause, all of these functions are affected at the same time.
COLLAGEN LOSS
This is one of the most significant skin impacts of oestrogen decline.
Studies show that skin collagen can decrease substantially in the first five years after menopause, then continue to decline year by year thereafter.
This rate can exceed the gradual collagen decline associated with chronological ageing, making the perimenopause to post-menopause transition one of the most important periods for skin collagen in a woman's life.
SKIN THICKNESS AND ELASTICITY
Oestrogen helps maintain dermal thickness by supporting both collagen and elastin production.
As oestrogen falls, skin becomes thinner and less elastic.
Thinner skin is more likely to show the structural changes beneath it, including fat redistribution and facial volume changes.
BARRIER FUNCTION AND HYDRATION
Oestrogen also supports ceramide production in the skin barrier and contributes to the natural moisturising factors that keep the outer layer hydrated.
When oestrogen declines, barrier lipid production can reduce, transepidermal water loss can increase, and skin can become more reactive and sensitised.
This overlaps directly with the barrier compromise many GLP-1 users experience through a different mechanism.
FAT REDISTRIBUTION
Menopause can contribute to redistribution of body fat from the subcutaneous layer to the visceral compartment.
Subcutaneous fat supports skin structure.
When that support changes, the face and body can look less full, less firm, or more hollowed.
Many women first notice these changes in their late 40s and early 50s, even without weight loss.
02. HOW GLP-1 COMPOUNDS THE MENOPAUSE SKIN PICTURE
Each mechanism of menopausal skin change has a GLP-1 counterpart.
When both are happening simultaneously, the effects can compound.
This is not simply menopause skin plus GLP-1 skin.
It is skin managing overlapping structural challenges at the same time.
| Mechanism | Menopause Effect | GLP-1 Compound Effect |
|---|---|---|
| Collagen production | Oestrogen decline reduces fibroblast stimulation and contributes to collagen loss. | DWAT disruption may suppress adipose-derived stem cell signalling, adding another collagen-support challenge. |
| Barrier function | Reduced ceramide production and increased transepidermal water loss from oestrogen decline. | Reduced sebum and GLP-1-related metabolic change can further deplete barrier lipids. |
| Skin hydration | Reduced natural moisturising factors and reduced dermal hyaluronan support. | Increased transepidermal water loss from both mechanisms can make dehydration more pronounced. |
| Volume and fat | Subcutaneous fat can redistribute from face and skin-supporting areas to visceral storage. | Rapid GLP-1 fat loss can remove remaining subcutaneous structural fat. |
| Skin sensitisation | Thinner, more reactive skin from reduced oestrogen. | GLP-1 barrier compromise can worsen reactivity on skin already sensitised by hormonal change. |
| Hair | Hormonal hair thinning from oestrogen and progesterone decline. | Telogen effluvium from rapid weight loss can add to hormonal hair changes. |
The compounded picture is not menopause skin and GLP-1 skin simply added together. It is skin managing oestrogen-driven collagen loss and GLP-1-driven collagen disruption simultaneously.
03. WHY THIS MATTERS FOR UK WOMEN SPECIFICALLY
In the UK, GLP-1 medications are often privately prescribed, and a significant number of users are women in their 40s and 50s.
This is the exact age range where perimenopause and early post-menopause are most prevalent.
The NHS estimates that millions of women in the UK are currently perimenopausal or menopausal.
Private GLP-1 prescription demand is also strong in this demographic.
That means the intersection of menopause and GLP-1 weight loss is not a niche edge case in the UK.
For many women, this is the central skin story.
Menopause brands address oestrogen loss.
Weight loss brands address general transformation.
Anti-ageing brands address chronological ageing.
But very few address the combined biological reality.
The women coming to ElastiK° are often navigating both, and they are doing it with skincare advice designed for one or the other, never both together. That is the gap this brand was built to understand.
04. THE SKINCARE RESPONSE FOR MENOPAUSE AND GLP-1 SKIN
The skincare protocol for the menopause and GLP-1 combination needs to address more mechanisms than either condition alone.
The Skin in Evolution™ System provides the formulations.
Here is how each ingredient category applies to this specific context.
| Ingredient | What It Does | Why for Menopause and GLP-1 Skin | In ElastiK° |
|---|---|---|---|
| Signal Peptides | Prompt fibroblast collagen synthesis by mimicking collagen breakdown signals. | Collagen may be suppressed from two directions: oestrogen decline reducing fibroblast stimulation and GLP-1-related DWAT disruption reducing ADSC signalling. Peptides send the production signal directly. | Collagen Architect Serum, Stage 2, and Regenesis Complex, Stage 4A. |
| Multi-weight Hyaluronic Acid | Binds and holds moisture at multiple skin depths, from surface to dermis. | Menopause can reduce natural moisturising factors and dermal hyaluronan. GLP-1 can increase transepidermal water loss. Multi-weight HA supports dehydration at several depths. | Hydration Continuum Gel, Stage 1. |
| Ceramides 1, 3, 6-II | Rebuild the lipid matrix, the barrier mortar between skin cells. | Menopause can reduce ceramide production, while GLP-1 can deplete sebum. Ceramides help support both lipid pathways overnight. | Resilience Matrix Night Cream, Stage 5. |
| Bakuchiol | Supports collagen gene expression and cellular renewal. | Menopause and GLP-1 skin may both be more sensitised and barrier-compromised. Bakuchiol offers collagen-supporting activity with better tolerability than many retinoid routines. | Evolve Serum, Stage 4B. |
| Niacinamide | Strengthens the barrier, supports ceramide synthesis, and helps calm visible inflammation. | Addresses barrier vulnerability from both mechanisms simultaneously and works alongside HA as a base layer. | Hydration Continuum Gel, Stage 1. |
05. THE COMPLETE PROTOCOL FOR MENOPAUSE AND GLP-1 SKIN
Given the compounded nature of the skin challenge, the full Skin in Evolution™ System is particularly relevant for women navigating menopause and GLP-1 weight loss simultaneously.
Each stage addresses mechanisms relevant to both conditions.
SKIN IN EVOLUTION™ SYSTEM HYDRATION CONTINUUM GEL
Multi-weight hyaluronic acid and niacinamide addressing both oestrogen-driven hydration changes and GLP-1-related transepidermal water loss.
This is the foundation step that helps all other stages work more effectively.
Apply on damp skin, always.
SKIN IN EVOLUTION™ SYSTEM COLLAGEN ARCHITECT SERUM
Signal peptides addressing oestrogen-driven fibroblast underactivity and GLP-1-related ADSC signalling disruption.
Use on the face, neck, and décolleté daily.
SKIN IN EVOLUTION™ SYSTEM ELASTIK° LED FACIAL MASK
Red and near-infrared LED designed to support fibroblast activity.
Use 3 to 5 times weekly.
This is the non-topical collagen-supporting step that amplifies Stage 2.
SKIN IN EVOLUTION™ SYSTEM REGENESIS COMPLEX
Peptide-rich body treatment for areas experiencing compounded menopausal fat redistribution and GLP-1 fat loss.
Use on stomach, inner arms, décolleté, and neck.
Apply to damp skin after showering every day.
SKIN IN EVOLUTION™ SYSTEM EVOLVE SERUM
Bakuchiol for collagen support and cellular renewal.
Designed for sensitised, oestrogen-thinned, and GLP-1-compromised skin.
Use 3 to 5 evenings per week.
SKIN IN EVOLUTION™ SYSTEM RESILIENCE MATRIX NIGHT CREAM
Ceramide-rich overnight barrier recovery addressing both oestrogen-related ceramide depletion and GLP-1-related lipid compromise.
Apply generously every evening as the final step.
06. HRT AND SKINCARE: HOW THEY WORK TOGETHER
Hormone replacement therapy, where prescribed and appropriate, directly addresses the oestrogen-driven component of menopause skin changes.
Studies show that oestrogen therapy may significantly reduce the rate of collagen loss in some women.
This makes HRT one of the most relevant medical interventions for the oestrogen side of the compounded picture.
HRT and the Skin in Evolution™ System address complementary mechanisms.
HRT supports oestrogen-driven collagen signalling from within.
The Skin in Evolution™ System, particularly Collagen Architect Serum and Regenesis Complex, supports GLP-1-related skin mechanisms from outside.
Neither replaces the other.
For women on HRT who are also on GLP-1 medication, continue to follow your prescriber's guidance and use skincare to support the skin-specific mechanisms HRT does not fully address.
Consider discussing the skin implications of both menopause and GLP-1 medication with your prescriber or a dermatologist who understands both contexts.
07. FAQ
IS IT SAFE TO USE GLP-1 MEDICATION DURING MENOPAUSE?
This is a medical question and should be discussed with your GP, prescriber, or prescribing clinician.
From a skincare perspective, the relevant point is that using GLP-1 medication during menopause can create a compounded skin challenge.
That means skin may need more comprehensive support than it would with either menopause or weight loss alone.
The Skin in Evolution™ System was formulated to address this compounded picture.
DOES MENOPAUSE MAKE GLP-1 SKIN CHANGES WORSE?
Yes, it can.
But this happens through a compounding mechanism rather than a simple addition.
Oestrogen decline can suppress collagen production through one pathway.
GLP-1-related DWAT disruption may suppress collagen support through another.
Both can compromise the skin barrier through different but simultaneous mechanisms.
The result is skin managing a greater structural challenge than either condition produces alone.
WHICH ELASTIK° PRODUCTS ARE MOST IMPORTANT FOR MENOPAUSE AND GLP-1 SKIN?
All stages of the Skin in Evolution™ System are relevant.
The most important starting points are Hydration Continuum Gel for dehydration, Collagen Architect Serum for facial collagen support, Regenesis Complex for body skin, and Resilience Matrix Night Cream for barrier recovery.
Evolve Serum adds bakuchiol for collagen and cellular renewal support, particularly valuable when the skin barrier is too sensitised for stronger retinoid routines.
I AM PERIMENOPAUSAL AND JUST STARTING MOUNJARO. WHAT SHOULD I DO FIRST?
Start the full protocol from week one.
Do not wait for visible skin changes.
The compounded collagen and barrier changes can begin before they are visible.
Apply Hydration Continuum Gel on damp skin every morning and evening.
Use Collagen Architect Serum every morning for facial collagen support.
Start Regenesis Complex immediately for body areas such as the stomach, inner arms, and décolleté.
Seal every evening with Resilience Matrix Night Cream.
Add the LED Mask three times weekly to support fibroblast activity.
RELATED ARTICLES FROM THE SKIN JOURNAL
Continue reading at elastikskin.com/blogs/the-skin-journal:
SOURCES
All sources are peer-reviewed or clinical sources and were hyperlinked for this Shopify version.
- Stevenson S, Thornton J. Effect of Estrogens on Skin Aging and the Potential Role of SERMs. Clinical Interventions in Aging.
Read the source on PubMed Central - Brincat MP et al. A Study of the Decrease of Skin Collagen Content, Skin Thickness, and Bone Mass in the Postmenopausal Woman. Obstetrics and Gynecology.
Read the source on PubMed - Haykal D, Hersant B, Cartier H, Meningaud JP. The Role of GLP-1 Agonists in Esthetic Medicine: Exploring the Impact of Semaglutide on Body Contouring and Skin Health. Journal of Cosmetic Dermatology.
Read the source on PubMed Central - Maheux R et al. A Randomized, Double-Blind, Placebo-Controlled Study on the Effect of Conjugated Estrogens on Skin Collagen. American Journal of Obstetrics and Gynecology.
Read the source on PubMed - Paschou SA et al. GLP-1RA and the Possible Skin Aging. PMC, National Institutes of Health.
Read the source on PubMed Central
0 comments